related drug information classesiron supplements dea classrx common brand namesferrlecit nulecit triferic how suppliedferrlecitironnulecit intravenous inj sol 1m l 125mg triferic hemodialysis pwd 272mg triferic hemodialysis sol 1m l 544mg dosage  indicationsfor the treatment of irondeficiency anemia for iron replacement irondeficiency anemia to maintain hemoglobin in patients with hemodialysisdependent chronic kidney disease triferic extracorporeal dialysate dosage adults add 272 mg 5 m l ampule to 25 gallons of bicarbonate concentrate or 272 mg 50 m l ampule or 1 powder packet to 25 gallons of bicarbonate concentrate to achieve a final concentration of iron in the dialysate of 110 mcgl 2 micromolar administer at each dialysis session for as long as patients are receiving maintenance hemodialysis therapy for chronic kidney disease ferric pyrophosphate citrate is not intended for use in patients receiving peritoneal dialysis and has not been studied in patients receiving home hemodialysis for the treatment of irondeficiency anemia in patients undergoing chronic hemodialysis who are receiving supplemental epoetin alfa therapy note in patients with irondeficiency anemia receiving hemodialysis and supplemental epoetin alfa therapy sufficient intravenous iron should be administered to maintain a serum ferritin of greater than 200 ngm l and transferrin saturation tsat greater than 20 the administration of iv iron is not routinely recommended if serum ferritin exceeds 500 ngm l dosages in excess of iron needs may lead to accumulation of iron in iron storage sites serum iron concentrations greater than 300 mcgd l may indicate iron poisoning note serum iron concentrations should be interpreted cautiously in the 24 hours following sodium ferric gluconate complex administration as many laboratory assays will falsely overestimate serum or transferrinbound iron by measuring iron still bound to the sodium ferric gluconate complex additionally when assessing iron overload use caution when interpreting serum ferritin concentrations in the week following sodium ferric gluconate complex administration during clinical studies serum ferritin exhibited a nonspecific rise which persisted for 5 days intravenous dosage expressed as elemental ironadults initially 125 mg iv administered either by iv infusion over 1 hour or iv injection over at least 10 minutes during each dialysis session most patients will require a minimum cumulative dose of 1 g of elemental iron divided and administered over 8 sequential dialysis sessions to replete iron stores however dosage requirements should be based on individual patient assessment and condition patients with serum ferritin below 100 ngm l or tsat less than 18 may need repletion doses of sodium ferric gluconate complex greater than 1 g to achieve optimal hemoglobin response patients may continue to require regular therapy with sodium ferric gluconate complex at the lowest dose necessary to maintain target hemoglobin and hematocrit concentrations and acceptable laboratory parameters of iron storage doses of 625 mg iv elemental iron twice weekly weekly or every 2 weeks has maintained iron stores and reduced the dose of epoetin alfa according to the manufacturer single doses exceeding 125 mg iv may be associated with a higher incidence andor severity of adverse reactions eg hypotension nausea vomiting abdominal pain diarrhea dizziness dyspnea urticaria chest pain paresthesia and peripheral swelling although single doses of 250 mg iv to 500 mg iv have been studied in various populations  adverse reactions were reported in some studies of note adrs were more common in patients receiving single doses of 500 mg iv compared to single doses of 250 mg iv children and adolescents 6 years and older15 mgkg iv over 1 hour during 8 sequential dialysis sessions do not exceed 125 mg per dose maximum dosageadults sodium ferric gluconate complex 125 mgdose iv higher doses may be associated with higher incidence andor severity of adverse reactions ferric pyrophosphate citrate maximum dosage is not defined dose is dependent on dialysate volume used during hemodialysis session geriatric sodium ferric gluconate complex 125 mgdose iv higher doses may be associated with higher incidence andor severity of adverse reactions ferric pyrophosphate citrate maximum dosage is not defined dose is dependent on dialysate volume used during hemodialysis session adolescents sodium ferric gluconate complex 125 mgdose iv ferric pyrophosphate citrate safety and efficacy have not been established children sodium ferric gluconate complex 6 years and older 125 mgdose iv less than 6 years safety and efficacy have not been established ferric pyrophosphate citrate safety and efficacy have not been established infants safety and efficacy have not been established neonates safety and efficacy have not been established dosing considerationshepatic impairment patients with hepatic disease should receive sodium ferric gluconate complex ferric pyrophosphate citrate with caution the liver is one of the main storage sites for iron and some patients with chronic liver disease may have excessive iron storage specific guidelines for dosage adjustments in hepatic impairment are not available renal impairment dosage adjustment is not necessary intermittent hemodialysis sodium ferric gluconate complex is not dialyzable and may be administered during dialysis administrationinjectable administration prior to and at regular intervals during iron therapy evaluate serum iron hemoglobin and hematocrit ferritin and transferrin are also recommended monitoring parameters visually inspect solution for particulate matter and discoloration prior to administration whenever solution and container permit intravenous administration sodium ferric gluconate complex administer by intravenous injection or infusion each 5 m l ampule of sodium ferric gluconate complex contains 625 mg of elemental iron 125 mgm l the dose of sodium ferric gluconate complex is expressed in terms of elemental iron an intravenous test dose was originally recommended prior to initiating the full dosage however the fda subsequently approved the use of the undiluted ferrlecit brand sodium ferric gluconate complex without a prior test dose intravenous injection may administer undiluted at a rate of 125 mgminute or less to prevent hypotension a test dose 25 mg iron diluted in 50 m l of 09 sodium chloride injection over 1 hour may be used but is no longer required prior to administration of ferrlecit do not mix or infuse with tpn or any intravenous fluid other than 09 sodium chloride injection intravenous infusion dilution dilute 125 mg of elemental iron 10 m l ferrlecit with 100 m l of 09 sodium chloride injection administer dosage immediately following dilution infuse over 60 minutes to prevent hypotension and flushing do not exceed the recommended rate of administration of 21 mgminute a test dose 25 mg iron diluted in 50 m l of 09 sodium chloride injection over 1 hour may be used but is no longer required prior to administration of ferrlecit do not mix or infuse with tpn or any intravenous fluid other than 09 sodium chloride injection other administration route sintravascular administration ferric pyrophosphate citrate ferric pyrophosphate citrate should only be added to the bicarbonate concentrate do not add to acid concentrate mixtures inspect each ampule for signs of precipitation prior to mixing with bicarbonate concentrate ferric pyrophosphate citrate should be slightly yellowgreen in color intravascular administration add 272 mg 5 m l ampule to 25 gallons of bicarbonate concentrate or 272 mg 50 m l ampule or 1 powder packet to 25 gallons of bicarbonate concentrate the final concentration of iron in the dialysate is 110 mcgl 2 micromolar multiple ampules may be added to the master bicarbonate mix at each dialysis center at a ratio of 272 mg 5 m l ampule to each 25 gallons of bicarbonate concentrate or 272 mg 50 m l ampule or 1 powder packet to each 25 gallons of bicarbonate concentrate administer at each dialysis session for as long as patients are receiving maintenance hemodialysis therapy for chronic kidney disease hemodialysis solutions should be used within 24 hours of the preparation of the ferric pyrophosphate citratebicarbonate concentrate mixture storageferrlecit  do not freeze  store between 68 to 77 degrees f excursions permitted 59 to 86 degrees f nulecit  do not freeze  store between 68 to 77 degrees f excursions permitted 59 to 86 degrees f triferic  store between 68 to 77 degrees f excursions permitted 59 to 86 degrees fcontraindications  precautionsgeneral information sodium ferric gluconate complex ferric pyrophosphate citrate is contraindicated in patients who are hypersensitive to the drug or any of its components sodium ferric gluconate complex should only be used in patients with a clear and confirmed need for parenteral iron therapy potentially fatal hypersensitivity reactions characterized by cardiovascular collapse cardiac arrest bronchospasm oral or pharyngeal edema dyspnea angioedema urticaria or pruritus which could result in death have been reported rarely in patients receiving therapy with ironcarbohydrate complexes parenteral sodium ferric gluconate complex ferrlecit and iron sucrose venofer complexes are less likely to cause hypersensitivity reactions than iron dextran and may be used as alternative therapy in patients with a prior hypersensitivity reaction to iron dextran in a postmarketing singledose safety study of 1097 patients 1 patient experienced a lifethreatening hypersensitivity reaction to sodium ferric gluconate complex furthermore the incidence of drug intolerance or suspected allergic reaction to sodium ferric gluconate complex occurred in 28 of patients with a history of prior iron dextran hypersensitivity including the patient with the life threatening reaction vs 08 of patients without such a history in addition 28 of patients in this study were also receiving an angiotensin converting enzyme ace inhibitor the incidence of drug intolerance or suspected hypersensitivity reaction in patients taking an ace inhibitor was 16 vs 07 in those patients not taking an ace inhibitor a test dose was initially recommended prior to administration of ferrlecit however the fda has removed this requirement for a test dose upon reviewing postmarketing safety data for ferrlecit serious anaphylactoid reactions require appropriate resuscitative measures cardiac disease geriatric hypotension cardiovascular adverse effects may also occur with sodium ferric gluconate complex and do not necessarily indicate hypersensitivity flushing and hypotension are more common following rapid intravenous administration see dosage for recommended administration rates for iv injection and iv infusion sodium ferric gluconate complex is administered commonly to patients receiving dialysis many patients experience transient hypotension during hemodialysis patients with preexisting cardiac disease may have exacerbation of cardiovascular symptoms if adverse effects occur following sodium ferric gluconate complex administration data in patients aged  65 years old are limited while geriatric patients do not appear to respond differently to this drug than normal adults the manufacturer has recommended cautious initial dosing in the elderly population intramuscular administration the only approved route of administration for sodium ferric gluconate complex is intravenously there is no information regarding intramuscular administration ferric pyrophosphate citrate is not intended for use in patients receiving peritoneal dialysis it has not been studied in patients receiving home hemodialysis hemochromatosis hemoglobinopathy hemosiderosis do not administer sodium ferric gluconate complex ferric pyrophosphate citrate to patients with evidence of iron overload eg patients with hemochromatosis unnecessary or prolonged administration of iron may lead to iron overload and consequently the possibility of exogenous hemosiderosis patients with hemoglobinopathy and other refractory anemias that might be erroneously diagnosed as iron deficiency anemias are at particular risk for such iron overload the type of anemia and the underlying cause or causes should be determined before starting therapy with parenteral sodium ferric gluconate complex since the anemia may be a result of a systemic disturbance such as recurrent blood loss the underlying cause s should be corrected if possible patients receiving exogenous iron therapy require periodic monitoring of hematologic and hematinic parameters ie hemoglobin hematocrit serum ferritin and transferrin saturation to avoid iron overload hepatic disease some patients with chronic hepatic disease may also have hemochromatosis or moderate iron overload in hepatic tissues the liver is one of the main storage sites for iron and advanced chronic liver disease may result in excess storage iron in the liver use sodium ferric gluconate complex ferric pyrophosphate citrate with caution in patients with hepatic disease pregnancy use sodium ferric gluconate complex or ferric pyrophosphate citrate in pregnant patients only if the potential benefit justifies the potential risk to the fetus sodium ferric gluconate complex is classified as fda pregnancy category b there are no adequate or wellcontrolled human studies with sodium ferric gluconate complex in pregnancy sodium ferric gluconate complex was not teratogenic at doses up to 100 mgkgday 300 mgm2day in mice and 20 mgkgday 120 mgm2day in rats these iron doses were 4 and 15 times the recommended human dose of 125 mgday 77 mgm2day on a body surface area basis and revealed no evidence of harm to the fetus no data are available regarding maternal toxicity sodium ferric gluconate complex injection products contain benzyl alcohol as a preservative although there are no known adverse outcomes associated with fetal exposure to the preservative benzyl alcohol can cause serious adverse events and death when administered intravenously to neonates and infants studies to assess the effects of sodium ferric gluconate complex on fertility were not conducted there are no available data on the use of ferric pyrophosphate citrate in pregnant women to inform a drugassociated risk of major birth defects or miscarriage in animal studies with ferric pyrophosphate citrate developmental toxicity was observed when animals were administered maternally toxic doses that were higher than the maximum theoretical amount of iron administered to humans breastfeeding use caution when administering sodium ferric gluconate complex injection to a breastfeeding woman while iron is excreted into breast milk the iron content of breast milk is not readily affected by the iron content of the maternal diet or the maternal serum iron concentration therefore iron use is usually compatible with breastfeeding if the lactating mother needs treatment for iron deficiency however sodium ferric gluconate complex injection products contain the preservative benzyl alcohol when present in maternal serum benzyl alcohol is likely to cross into breast milk and may be orally absorbed by a nursing infant benzyl alcohol has been associated with gasping syndrome in neonates and lowbirth weight infants although a normal therapeutic dose of sodium ferric gluconate complex delivers a much smaller amount of benzyl alcohol than has been associated with gasping syndrome the potential for serious adverse events from exposure to benzyl alcohol especially in a neonate or lowbirth weight infant should be considered there is no information regarding the presence of ferric pyrophosphate citrate in human milk the effects on the breastfed child or the effects on milk production consider the developmental and health benefits of breastfeeding along with the mothers clinical need for ferric pyrophosphate citrate and any potential adverse effects on the breastfed child from ferric pyrophosphate citrate or the underlying maternal condition benzyl alcohol hypersensitivity children infants neonates safety and effectiveness of the use of sodium ferric gluconate complex has not been established in infants or children  6 years of age administration of iron to premature infants can increase the risk of developing hemolytic anemia because these infants may have a low serum vitamin e concentration in general iron supplementation should not begin in premature infants until adequate vitamin e is supplied in the diet human breast milk and modern infant formulas usually supply adequate vitamin e sodium ferric gluconate complex should be avoided in patients with benzyl alcohol hypersensitivity and should not be used in neonates because of the presence of benzyl alcohol as a preservative in the product in neonates benzyl alcohol may cause a gasping syndrome neonates have a decreased capacity to conjugate pamino benzoate and benzoic acid benzoic acid accumulation in neonates may cause significant morbidity sodium ferric gluconate complex has been shown to be safe and effective in children aged 6 to 15 years two dosages of sodium ferric gluconate complex 15 mgkg or 30 mgkg were administered to 66 irondeficient pediatric hemodialysis patients aged 6 to 15 years for 8 sequential dialysis sessions two weeks after the last dose of sodium ferric gluconate complex was administered both groups of patients demonstrated significant increases in hemoglobin 08 mgd l for the 15 mgkg group and 09 mgd l for the 30 mgkg group p  003 compared to baseline for both groups in addition both groups demonstrated significant increases in hematocrit transferrin saturation and serum ferritin concentrations there were no statistically significant differences between the two groups contraception requirements reproductive risk ferric pyrophosphate citrate may be associated with reproductive risk fetal harm discuss contraception requirements with the patient advise females of reproductive potential to use effective contraception measures to prevent pregnancy during treatment with ferric pyrophosphate citrate and for at least 2 weeks after completion of therapy adverse reactionsseverethrombosis  delayed  3460 hyperkalemia  delayed  6060 seizures  delayed  incidence not known myocardial infarction  delayed  incidence not known pulmonary edema  early  incidence not known bradycardia  rapid  incidence not known anaphylactoid reactions  rapid  incidence not known angioedema  rapid  incidence not known bronchospasm  rapid  incidence not known cardiac arrest  early  incidence not known cyanosis  early  incidence not known hearing loss  delayed  incidence not known moderatehypotension  rapid  216410 hypertension  early  130230 sinus tachycardia  rapid  50210 dyspnea  early  58110 chest pain unspecified  early  100100 peripheral edema  delayed  6868 bleeding  early  3434 hypertonia  delayed  incidence not known peripheral vasodilation  rapid  incidence not known angina  early  incidence not known constipation  delayed  incidence not known melena  delayed  incidence not known lymphadenopathy  delayed  incidence not known anemia  delayed  incidence not known phlebitis  rapid  incidence not known wheezing  rapid  incidence not known flank pain  delayed  incidence not known edema  delayed  incidence not known metabolic acidosis  delayed  incidence not known hemosiderosis  delayed  incidence not known conjunctivitis  delayed  incidence not known hypervolemia  delayed  incidence not known hypoglycemia  early  incidence not known hypokalemia  delayed  incidence not known mildnausea  early  60350 vomiting  early  90350 diarrhea  early  80350 injection site reaction  rapid  330330 headache  early  70290 abdominal pain  early  30150 fever  early  30150 dizziness  early  130130 pharyngitis  delayed  60120 muscle cramps  delayed  9696 rhinitis  early  3090 infection  delayed  4580 asthenia  delayed  4170 fatigue  early  3860 paresthesias  delayed  6060 cough  delayed  6060 syncope  early  6060 pruritus  rapid  6060 back pain  delayed  4545 drowsiness  early  incidence not known agitation  early  incidence not known malaise  early  incidence not known hypoesthesia  delayed  incidence not known weakness  early  incidence not known eructation  early  incidence not known xerostomia  early  incidence not known flatulence  early  incidence not known dysgeusia  early  incidence not known anorexia  delayed  incidence not known dyspepsia  early  incidence not known leukocytosis  delayed  incidence not known hyperhidrosis  delayed  incidence not known skin discoloration  delayed  incidence not known pallor  early  incidence not known urticaria  rapid  incidence not known musculoskeletal pain  early  incidence not known chills  rapid  incidence not known myalgia  early  incidence not known arthralgia  delayed  incidence not known flushing  rapid  incidence not known diaphoresis  early  incidence not known hyperventilation  early  incidence not known menorrhagia  delayed  incidence not known diplopia  early  incidence not known drug interactionsabacavir dolutegravir lamivudine moderate administer dolutegravir 2 hours before or 6 hours after taking orally administered iron salts alternatively these drugs may be given concurrently if administered with food iron is a polyvalent cation that can bind dolutegravir in the gi tract taking these drugs simultaneously without food results in reduced bioavailability of dolutegravir acetohydroxamic acid moderate acetohydroxamic acid chelates heavy metals including iron absorption of orally administered iron salts or polysaccharideiron complex and acetohydroxamic acid from the intestinal lumen may be reduced when both drugs are administered concomitantly if iron therapy is required in a patient currently taking acetohydroxamic acid intramuscular iron is recommended amoxicillin clarithromycin lansoprazole major the bioavailability of oral iron salts is influenced by gastric p h and the concomitant administration of proton pump inhibitors can decrease iron absorption the nonheme ferric form of iron needs an acidic intragastric p h to be reduced to ferrous and to be absorbed iron salts and polysaccharideiron complex provide nonheme iron proton pump inhibitors have longlasting effects on the secretion of gastric acid and thus increase the p h of the stomach the increase in intragastric p h can interfere with the absorption of iron salts amoxicillin clarithromycin omeprazole major the bioavailability of oral iron salts is influenced by gastric p h and the concomitant administration of proton pump inhibitors can decrease iron absorption the nonheme ferric form of iron needs an acidic intragastric p h to be reduced to ferrous and to be absorbed iron salts and polysaccharideiron complex provide nonheme iron proton pump inhibitors have longlasting effects on the secretion of gastric acid and thus increase the p h of the stomach the increase in intragastric p h can interfere with the absorption of iron salts antacids major antacids may decrease the absorption of oral iron preparations at higher p h values iron is more readily ionized to its ferric state and is more poorly absorbed doses of antacids and iron should be taken as far apart as possible to minimize the potential for interaction aspirin asa omeprazole major the bioavailability of oral iron salts is influenced by gastric p h and the concomitant administration of proton pump inhibitors can decrease iron absorption the nonheme ferric form of iron needs an acidic intragastric p h to be reduced to ferrous and to be absorbed iron salts and polysaccharideiron complex provide nonheme iron proton pump inhibitors have longlasting effects on the secretion of gastric acid and thus increase the p h of the stomach the increase in intragastric p h can interfere with the absorption of iron salts bictegravir emtricitabine tenofovir alafenamide moderate administer bictegravir with food at the same time as iron supplements routine administration of bictegravir under fasting conditions simultaneously with or 2 hours after iron supplements is not recommended iron is a polyvalent cation that can bind bictegravir in the gi tract taking these drugs simultaneously without food results in reduced bioavailability of bictegravir in drug interaction studies simultaneous administration of bictegravir and ferrous fumarate under fasted conditions decreased the mean auc of bictegravir by approximately 63 bisphosphonates moderate separating times of administration of the oral bisphosphonate from ironcontaining supplements and medications will maximize absorption and clinical benefit iron will interfere with the absorption of the orally administered bisphosphonates alendronate etidronate ibandronate risedronate and tiludronate at least 30 minutes should elapse after the oral administration of alendronate before taking any iron containing product at least 1 hour should elapse after the oral administration of ibandronate before taking any iron containing product at least 2 hours should elapse after the oral administration of etidronate risedronate or tiludronate before administering any calcium containing product calcium carbonate major antacids eg calcium carbonate aluminum hydroxide or magnesium hydroxide may decrease the absorption of oral iron preparations eg iron salts or polysaccharideiron complex at higher p h values iron is more readily ionized to its ferric state and is more poorly absorbed doses of antacids and iron should be taken as far apart as possible to minimize the potential for interaction calcium carbonate magnesium hydroxide major antacids eg calcium carbonate aluminum hydroxide or magnesium hydroxide may decrease the absorption of oral iron preparations eg iron salts or polysaccharideiron complex at higher p h values iron is more readily ionized to its ferric state and is more poorly absorbed doses of antacids and iron should be taken as far apart as possible to minimize the potential for interaction calcium carbonate risedronate major antacids eg calcium carbonate aluminum hydroxide or magnesium hydroxide may decrease the absorption of oral iron preparations eg iron salts or polysaccharideiron complex at higher p h values iron is more readily ionized to its ferric state and is more poorly absorbed doses of antacids and iron should be taken as far apart as possible to minimize the potential for interaction calcium vitamin d major antacids eg calcium carbonate aluminum hydroxide or magnesium hydroxide may decrease the absorption of oral iron preparations eg iron salts or polysaccharideiron complex at higher p h values iron is more readily ionized to its ferric state and is more poorly absorbed doses of antacids and iron should be taken as far apart as possible to minimize the potential for interaction carbidopa levodopa major iron salts may reduce the bioavailability of levodopa and carbidopa levodopa administration of iron salts including polysaccharideiron complex should be separated from levodopa by at least 2 hours carbidopa levodopa entacapone major iron salts may reduce the bioavailability of levodopa and carbidopa levodopa administration of iron salts including polysaccharideiron complex should be separated from levodopa by at least 2 hours cefdinir major concomitant administration of cefdinir with therapeutic iron supplements containing 60 mg of elemental iron or vitamins supplemented with 10 mg of elemental iron reduced extent of cefdinir absorption by 80 and 31 respectively if oral iron supplements are required during cefdinir therapy cefdinir should be taken at least 2 hours before or 2 hours after the iron supplement the effect highly ironfortified food primarily ironfortified breakfast cereals on cefdinir absorption has not been studied further concomitantly administered ironfortified infant formula 22 mg elemental iron6 oz has no significant effect on cefdinir pharmacokinetics therefore cefdinir oral suspension can be administered with ironfortified infant formula however several case reports describe nonbloody reddish stool discoloration in infants being treated with cefdinir who were also receiving ironfortified infant formulas this reddish color may occur as a result of the formation of a nonabsorbable complex between ferric ions and cefdinir or one of its metabolites parents of infants receiving cefdinir should be counseled about this potential interaction cholestyramine moderate concurrent administration of cholestyramine and oral iron supplements may reduce the oral absorption of iron to avoid any oral absorption interference administration of other drugs is recommended 1 hour before or at least 4 to 6 hours after cholestyramine administration cimetidine minor the bioavailability of oral iron salts is influenced by gastric p h and the concomitant administration of h2blockers can decrease iron absorption the nonheme ferric form of iron needs an acidic intragastric p h to be reduced to ferrous and to be absorbed iron salts and polysaccharideiron complex provide nonheme iron h2blockers have longlasting effects on the secretion of gastric acid and thus increase the p h of the stomach the increase in intragastric p h can interfere with the absorption of iron salts ciprofloxacin major administer oral ciprofloxacin at least 2 hours before or 6 hours after oral products that contain iron ciprofloxacin absorption may be reduced as quinolone antibiotics can chelate with divalent or trivalent cations examples of compounds that may interfere with quinolone bioavailability include multivitamins that contain iron cyanocobalamin vitamin b12 moderate it has been reported that high intakes of phosphates such as are found in dietary supplements or food additives can interfere with absorption of trace nutrients such as iron copper and zinc the magnitude of the effect may be small and the interactions require further study to judge clinical significance the theorized mechanism is the formation of insoluble complexes within the gut until more data are available it may be helpful to separate administration times of phosphates by as much as possible from the oral administration of iron eg iron salts or polysaccharideiron complex copper salts or zinc salts to limit any potential interactions darbepoetin alfa minor it is important that iron stores be replete before beginning therapy with darbepoetin alfa due to increased iron utilization inadequate iron stores will interfere with the therapeutic response to these agents eg red blood cell production supplemental iron may be needed during maintenance therapy to facilitate erythropoiesis iron supplementation eg iron dextran iron salts iron sucrose sucroferric oxyhydroxide polysaccharideiron complex sodium ferric gluconate complex may be required deferasirox severe deferasirox chelates iron and is indicated as a treatment of iron toxicity or overdose it is illogical for a patient to receive both iron supplementation and deferasirox simultaneously do not give iron supplementation during deferasirox treatment deferiprone major deferiprone chelates iron therapeutically it is typically illogical for a patient to receive both iron supplementation eg iron salts iron dextran iron sucrose sodium ferric gluconate complex or polysaccharideiron complex and deferiprone simultaneously concurrent use of deferiprone with iron supplements has not been studied however since deferiprone has the potential to bind polyvalent cations eg iron allow at least a 4hour interval between deferiprone and other oral medications or dietary supplements containing these polyvalent cations when they are used deferoxamine severe deferoxamine chelates iron from ferritin or hemosiderin a stable complex is formed that prevents iron from entering into further chemical reactions the chelate is excreted in the urine and in the feces via bile deferoxamine is indicated as a treatment of iron toxicity or overdose it would be illogical for a patient to receive both iron supplementation and deferoxamine simultaneously delafloxacin major administer oral delafloxacin at least 2 hours before or 6 hours after oral products that contain iron delafloxacin absorption may be reduced as quinolone antibiotics can chelate with divalent or trivalent cations examples of compounds that may interfere with quinolone bioavailability include multivitamins that contain iron dexlansoprazole major the bioavailability of oral iron salts is influenced by gastric p h and the concomitant administration of proton pump inhibitors can decrease iron absorption the nonheme ferric form of iron needs an acidic intragastric p h to be reduced to ferrous and to be absorbed iron salts and polysaccharideiron complex provide nonheme iron proton pump inhibitors have longlasting effects on the secretion of gastric acid and thus increase the p h of the stomach the increase in intragastric p h can interfere with the absorption of iron salts didanosine dd i moderate iron salts should not be administered simultaneously with didanosine dd i chewable tablets or powder for oral solution oral absorption of iron supplements is reduced if given with antacids the buffering agents contained in didanosine tablets and powder likewise reduce iron salt absorption administer oral doses of iron salts 1 hour before or 4 hours after didanosine tablet or powder administration the delayedrelease didanosine capsules do not contain a buffering agent and would not be expected to interact with iron salts dimercaprol severe dimercaprol forms toxicchelates with iron these dimercaprolmetal complexes are more toxic than the metal alone especially to the kidneys iron therapy should not be administered concomitantly with dimercaprol therapy with iron should generally be delayed until 24 hours after the cessation of dimercaprol therapy dolutegravir moderate administer dolutegravir 2 hours before or 6 hours after taking orally administered iron salts alternatively these drugs may be given concurrently if administered with food iron is a polyvalent cation that can bind dolutegravir in the gi tract taking these drugs simultaneously without food results in reduced bioavailability of dolutegravir dolutegravir rilpivirine moderate administer dolutegravir 2 hours before or 6 hours after taking orally administered iron salts alternatively these drugs may be given concurrently if administered with food iron is a polyvalent cation that can bind dolutegravir in the gi tract taking these drugs simultaneously without food results in reduced bioavailability of dolutegravir eltrombopag major eltrombopag chelates polyvalent cations eg iron in foods and mineral supplements in a clinical study systemic exposure to eltrombopag was decreased by 70 when it was administered with a polyvalent cationcontaining antacid administer eltrombopag at least 2 hours before or 4 hours after any oral products containing polyvalent cations such as iron salts multivitamins that contain iron or polysaccharideiron complex epoetin alfa minor inadequate iron stores will interfere with the therapeutic response to epoetin alfa eg red blood cell production most patients with chronic kidney disease will require supplemental iron eg iron dextran iron salts iron sucrose sucroferric oxyhydroxide polysaccharideiron complex sodium ferric gluconate complex during epoetin alfa receipt evaluate transferrin saturation and serum ferritin before and during epoetin alfa treatment administer supplemental iron therapy when serum ferritin is  100 mcgl or when serum transferrin saturation is  20 after initiation of therapy and after each dose adjustment monitor hemoglobin weekly until the hemoglobin concentration is stable and sufficient to minimize the need for rbc transfusion esomeprazole major the bioavailability of oral iron salts is influenced by gastric p h and the concomitant administration of proton pump inhibitors can decrease iron absorption the nonheme ferric form of iron needs an acidic intragastric p h to be reduced to ferrous and to be absorbed iron salts and polysaccharideiron complex provide nonheme iron proton pump inhibitors have longlasting effects on the secretion of gastric acid and thus increase the p h of the stomach the increase in intragastric p h can interfere with the absorption of iron salts esomeprazole naproxen major the bioavailability of oral iron salts is influenced by gastric p h and the concomitant administration of proton pump inhibitors can decrease iron absorption the nonheme ferric form of iron needs an acidic intragastric p h to be reduced to ferrous and to be absorbed iron salts and polysaccharideiron complex provide nonheme iron proton pump inhibitors have longlasting effects on the secretion of gastric acid and thus increase the p h of the stomach the increase in intragastric p h can interfere with the absorption of iron salts famotidine minor the bioavailability of oral iron salts is influenced by gastric p h and the concomitant administration of h2blockers can decrease iron absorption the nonheme ferric form of iron needs an acidic intragastric p h to be reduced to ferrous and to be absorbed iron salts and polysaccharideiron complex provide nonheme iron h2blockers have longlasting effects on the secretion of gastric acid and thus increase the p h of the stomach the increase in intragastric p h can interfere with the absorption of iron salts famotidine ibuprofen minor the bioavailability of oral iron salts is influenced by gastric p h and the concomitant administration of h2blockers can decrease iron absorption the nonheme ferric form of iron needs an acidic intragastric p h to be reduced to ferrous and to be absorbed iron salts and polysaccharideiron complex provide nonheme iron h2blockers have longlasting effects on the secretion of gastric acid and thus increase the p h of the stomach the increase in intragastric p h can interfere with the absorption of iron salts ferric carboxymaltose severe parenteral irom formulas are generally only indicated for use in patients with documented iron deficiency in whom oral administration is either impossible or unsatisfactory in general do not administer parenteral iron concomitantly with other iron preparations egother parenteral iron products or oral iron supplements parenteral iron preparations eg iron dextran iron sucrose sucroferric oxyhydroxide sodium ferric gluconate complex ferric carboxymaltose ferumoxytol may reduce the absorption of concomitantly administered oral iron preparations oral iron supplementation should be discontinued before parenteral administration of iron too much iron can be toxic and iron is not easily eliminated from the body ferric citrate major concurrent use of ferric citrate with other iron preparations eg iron dextran iron salts iron sucrose sucroferric oxyhydroxide polysaccharideiron complex sodium ferric gluconate complex iron dextran iron sucrose sucroferric oxyhydroxide sodium ferric gluconate complex ferric carboxymaltose ferumoxytol may result in excessive elevations in iron stores too much iron can be toxic and iron is not easily eliminated from the body monitor iron parameters routinely in patients receiving ferric citrate ferumoxytol severe parenteral irom formulas are generally only indicated for use in patients with documented iron deficiency in whom oral administration is either impossible or unsatisfactory in general do not administer parenteral iron concomitantly with other iron preparations egother parenteral iron products or oral iron supplements parenteral iron preparations eg iron dextran iron sucrose sucroferric oxyhydroxide sodium ferric gluconate complex ferric carboxymaltose ferumoxytol may reduce the absorption of concomitantly administered oral iron preparations oral iron supplementation should be discontinued before parenteral administration of iron too much iron can be toxic and iron is not easily eliminated from the body gemifloxacin major administer oral products that contain iron at least 3 hours before or 2 hours after gemifloxacin gemifloxacin absorption may be reduced as quinolone antibiotics can chelate with divalent or trivalent cations examples of compounds that may interfere with quinolone bioavailability include multivitamins that contain iron green tea major green tea has been shown to inhibit the absorption of nonheme iron when possible do not consume green tea or green tea extract within 1 hour before or 2 hours after giving iron salts h2blockers minor the bioavailability of oral iron salts is influenced by gastric p h and the concomitant administration of h2blockers can decrease iron absorption the nonheme ferric form of iron needs an acidic intragastric p h to be reduced to ferrous and to be absorbed iron salts and polysaccharideiron complex provide nonheme iron h2blockers have longlasting effects on the secretion of gastric acid and thus increase the p h of the stomach the increase in intragastric p h can interfere with the absorption of iron salts hydrochlorothiazide hctz methyldopa major coadministration of methyldopa with iron salts or polysaccharideiron complex is not recommended if iron supplementation is necessary administer a methyldopa dose at least 2 hours prior to the iron supplement iron salts have been reported to dramatically reduce the oral absorption of methyldopa several studies demonstrate decreased bioavailability of methyldopa when coadministered with ferrous sulfate or ferrous gluconate this interaction may result in decreased antihypertensive effect of methyldopa ibritumomab tiuxetan moderate it has been reported that high intakes of phosphates such as are found in dietary supplements or food additives can interfere with absorption of trace nutrients such as iron copper and zinc the magnitude of the effect may be small and the interactions require further study to judge clinical significance the theorized mechanism is the formation of insoluble complexes within the gut until more data are available it may be helpful to separate administration times of phosphates by as much as possible from the oral administration of iron eg iron salts or polysaccharideiron complex copper salts or zinc salts to limit any potential interactions iron  injectable only severe parenteral irom formulas are generally only indicated for use in patients with documented iron deficiency in whom oral administration is either impossible or unsatisfactory in general do not administer parenteral iron concomitantly with other iron preparations egother parenteral iron products or oral iron supplements parenteral iron preparations eg iron dextran iron sucrose sucroferric oxyhydroxide sodium ferric gluconate complex ferric carboxymaltose ferumoxytol may reduce the absorption of concomitantly administered oral iron preparations oral iron supplementation should be discontinued before parenteral administration of iron too much iron can be toxic and iron is not easily eliminated from the body iron dextran severe parenteral irom formulas are generally only indicated for use in patients with documented iron deficiency in whom oral administration is either impossible or unsatisfactory in general do not administer parenteral iron concomitantly with other iron preparations egother parenteral iron products or oral iron supplements parenteral iron preparations eg iron dextran iron sucrose sucroferric oxyhydroxide sodium ferric gluconate complex ferric carboxymaltose ferumoxytol may reduce the absorption of concomitantly administered oral iron preparations oral iron supplementation should be discontinued before parenteral administration of iron too much iron can be toxic and iron is not easily eliminated from the body iron sucrose sucroferric oxyhydroxide severe parenteral irom formulas are generally only indicated for use in patients with documented iron deficiency in whom oral administration is either impossible or unsatisfactory in general do not administer parenteral iron concomitantly with other iron preparations egother parenteral iron products or oral iron supplements parenteral iron preparations eg iron dextran iron sucrose sucroferric oxyhydroxide sodium ferric gluconate complex ferric carboxymaltose ferumoxytol may reduce the absorption of concomitantly administered oral iron preparations oral iron supplementation should be discontinued before parenteral administration of iron too much iron can be toxic and iron is not easily eliminated from the body lansoprazole major the bioavailability of oral iron salts is influenced by gastric p h and the concomitant administration of proton pump inhibitors can decrease iron absorption the nonheme ferric form of iron needs an acidic intragastric p h to be reduced to ferrous and to be absorbed iron salts and polysaccharideiron complex provide nonheme iron proton pump inhibitors have longlasting effects on the secretion of gastric acid and thus increase the p h of the stomach the increase in intragastric p h can interfere with the absorption of iron salts lansoprazole naproxen major the bioavailability of oral iron salts is influenced by gastric p h and the concomitant administration of proton pump inhibitors can decrease iron absorption the nonheme ferric form of iron needs an acidic intragastric p h to be reduced to ferrous and to be absorbed iron salts and polysaccharideiron complex provide nonheme iron proton pump inhibitors have longlasting effects on the secretion of gastric acid and thus increase the p h of the stomach the increase in intragastric p h can interfere with the absorption of iron salts lanthanum carbonate major oral compounds known to interact with antacids like iron salts should not be taken within 2 hours of dosing with lanthanum carbonate if these agents are used concomitantly space the dosing intervals appropriately monitor serum concentrations and clinical condition levodopa major iron salts may reduce the bioavailability of levodopa and carbidopa levodopa administration of iron salts including polysaccharideiron complex should be separated from levodopa by at least 2 hours levofloxacin major administer oral products that contain iron at least 2 hours before or 2 hours after orally administered levofloxacin levofloxacin absorption may be reduced as quinolone antibiotics can chelate with divalent or trivalent cations chelation of divalent cations with levofloxacin is less than with other quinolones examples of compounds that may interfere with quinolone bioavailability include multivitamins that contain iron methoxy polyethylene glycolepoetin beta minor iron stores should be replete before and during treatment with an esa iron stores are utilized in erythropoiesis and can be depleted during therapy even in patients with normal pretreatment iron concentrations achieving and maintaining adequate iron stores are essential to attaining an optimal response to mpgepoetin beta iron supplementation may be needed before and during therapy eg iron dextran iron salts sodium ferric gluconate complex iron sucrose sucroferric oxyhydroxide and polysaccharideiron complex methyldopa major coadministration of methyldopa with iron salts or polysaccharideiron complex is not recommended if iron supplementation is necessary administer a methyldopa dose at least 2 hours prior to the iron supplement iron salts have been reported to dramatically reduce the oral absorption of methyldopa several studies demonstrate decreased bioavailability of methyldopa when coadministered with ferrous sulfate or ferrous gluconate this interaction may result in decreased antihypertensive effect of methyldopa moxifloxacin major administer oral moxifloxacin at least 4 hours before or 8 hours after oral products that contain iron moxifloxacin absorption may be reduced as quinolone antibiotics can chelate with divalent or trivalent cations examples of compounds that may interfere with quinolone bioavailability include multivitamins that contain iron mycophenolate major conflicting information has been reported regarding coadministration of mycophenolate and iron salts due to the discrepant findings and study differences additional data are needed to clarify the potential interaction between iron salts and mmf until more information is available avoid concurrent administration of mycophenolate mofetil and oral iron salts including polysaccharideiron complex if possible nizatidine minor the bioavailability of oral iron salts is influenced by gastric p h and the concomitant administration of h2blockers can decrease iron absorption the nonheme ferric form of iron needs an acidic intragastric p h to be reduced to ferrous and to be absorbed iron salts and polysaccharideiron complex provide nonheme iron h2blockers have longlasting effects on the secretion of gastric acid and thus increase the p h of the stomach the increase in intragastric p h can interfere with the absorption of iron salts norfloxacin major administer oral products that contain iron at least 2 hours before or 2 hours after norfloxacin norfloxacin absorption may be reduced as quinolone antibiotics can chelate with divalent or trivalent cations examples of compounds that may interfere with quinolone bioavailability include multivitamins that contain iron ofloxacin major administer oral products that contain iron at least 2 hours before or 2 hours after ofloxacin ofloxacin absorption may be reduced as quinolone antibiotics can chelate with divalent or trivalent cations examples of compounds that may interfere with quinolone bioavailability include multivitamins that contain iron omeprazole major the bioavailability of oral iron salts is influenced by gastric p h and the concomitant administration of proton pump inhibitors can decrease iron absorption the nonheme ferric form of iron needs an acidic intragastric p h to be reduced to ferrous and to be absorbed iron salts and polysaccharideiron complex provide nonheme iron proton pump inhibitors have longlasting effects on the secretion of gastric acid and thus increase the p h of the stomach the increase in intragastric p h can interfere with the absorption of iron salts omeprazole sodium bicarbonate major antacids may decrease the absorption of oral iron preparations at higher p h values iron is more readily ionized to its ferric state and is more poorly absorbed doses of antacids and iron should be taken as far apart as possible to minimize the potential for interaction major the bioavailability of oral iron salts is influenced by gastric p h and the concomitant administration of proton pump inhibitors can decrease iron absorption the nonheme ferric form of iron needs an acidic intragastric p h to be reduced to ferrous and to be absorbed iron salts and polysaccharideiron complex provide nonheme iron proton pump inhibitors have longlasting effects on the secretion of gastric acid and thus increase the p h of the stomach the increase in intragastric p h can interfere with the absorption of iron salts pantoprazole major the bioavailability of oral iron salts is influenced by gastric p h and the concomitant administration of proton pump inhibitors can decrease iron absorption the nonheme ferric form of iron needs an acidic intragastric p h to be reduced to ferrous and to be absorbed iron salts and polysaccharideiron complex provide nonheme iron proton pump inhibitors have longlasting effects on the secretion of gastric acid and thus increase the p h of the stomach the increase in intragastric p h can interfere with the absorption of iron salts penicillamine major in general oral mineral supplements should not be given since they may block the oral absorption of penicillamine however iron deficiency may develop especially in children and menstruating or pregnant women or as a result of the low copper diet recommended for wilsons disease if necessary iron may be given in short courses but since iron and penicillamine each inhibit oral absorption of the other 2 hours should elapse between administration of penicillamine and iron doses phosphorated carbohydrate solution moderate it has been reported that high intakes of phosphates such as are found in dietary supplements or food additives can interfere with absorption of trace nutrients such as iron copper and zinc the magnitude of the effect may be small and the interactions require further study to judge clinical significance the theorized mechanism is the formation of insoluble complexes within the gut until more data are available it may be helpful to separate administration times of phosphates by as much as possible from the oral administration of iron eg iron salts or polysaccharideiron complex copper salts or zinc salts to limit any potential interactions phosphorus salts moderate it has been reported that high intakes of phosphates such as are found in dietary supplements or food additives can interfere with absorption of trace nutrients such as iron copper and zinc the magnitude of the effect may be small and the interactions require further study to judge clinical significance the theorized mechanism is the formation of insoluble complexes within the gut until more data are available it may be helpful to separate administration times of phosphates by as much as possible from the oral administration of iron eg iron salts or polysaccharideiron complex copper salts or zinc salts to limit any potential interactions phosphorus moderate it has been reported that high intakes of phosphates such as are found in dietary supplements or food additives can interfere with absorption of trace nutrients such as iron copper and zinc the magnitude of the effect may be small and the interactions require further study to judge clinical significance the theorized mechanism is the formation of insoluble complexes within the gut until more data are available it may be helpful to separate administration times of phosphates by as much as possible from the oral administration of iron eg iron salts or polysaccharideiron complex copper salts or zinc salts to limit any potential interactions potassium phosphate sodium phosphate moderate it has been reported that high intakes of phosphates such as are found in dietary supplements or food additives can interfere with absorption of trace nutrients such as iron copper and zinc the magnitude of the effect may be small and the interactions require further study to judge clinical significance the theorized mechanism is the formation of insoluble complexes within the gut until more data are available it may be helpful to separate administration times of phosphates by as much as possible from the oral administration of iron eg iron salts or polysaccharideiron complex copper salts or zinc salts to limit any potential interactions proton pump inhibitors major the bioavailability of oral iron salts is influenced by gastric p h and the concomitant administration of proton pump inhibitors can decrease iron absorption the nonheme ferric form of iron needs an acidic intragastric p h to be reduced to ferrous and to be absorbed iron salts and polysaccharideiron complex provide nonheme iron proton pump inhibitors have longlasting effects on the secretion of gastric acid and thus increase the p h of the stomach the increase in intragastric p h can interfere with the absorption of iron salts rabeprazole major the bioavailability of oral iron salts is influenced by gastric p h and the concomitant administration of proton pump inhibitors can decrease iron absorption the nonheme ferric form of iron needs an acidic intragastric p h to be reduced to ferrous and to be absorbed iron salts and polysaccharideiron complex provide nonheme iron proton pump inhibitors have longlasting effects on the secretion of gastric acid and thus increase the p h of the stomach the increase in intragastric p h can interfere with the absorption of iron salts ranitidine minor the bioavailability of oral iron salts is influenced by gastric p h and the concomitant administration of h2blockers can decrease iron absorption the nonheme ferric form of iron needs an acidic intragastric p h to be reduced to ferrous and to be absorbed iron salts and polysaccharideiron complex provide nonheme iron h2blockers have longlasting effects on the secretion of gastric acid and thus increase the p h of the stomach the increase in intragastric p h can interfere with the absorption of iron salts sodium bicarbonate major antacids may decrease the absorption of oral iron preparations at higher p h values iron is more readily ionized to its ferric state and is more poorly absorbed doses of antacids and iron should be taken as far apart as possible to minimize the potential for interaction sodium picosulfate magnesium oxide anhydrous citric acid moderate iron salts may chelate with the magnesium in sodium picosulfate magnesium oxide anhydrous citric acid solution therefore products containing iron should be taken at least 2 hours before and not less than 6 hours after the administration of sodium picosulfate magnesium oxide anhydrous citric acid solution tetracyclines major iron salts or products that contain iron can decrease the oral bioavailability of tetracyclines the ability of tetracyclines to chelate with divalent cations such as iron however varies depending on the particular antibiotic and when the antibiotic is administered with regard to the ironcontaining product doxycycline chelates more avidly with iron than other tetracyclines this pharmacokinetic interaction with iron can be minimized by staggering the doses of the antibiotic and iron by as much as possible administering ironcontaining products 4 to 6 hours before or 1 hour after the oral tetracycline antibiotic dose will minimize the risk of antibiotic failure due to poor bioavailability thyroid hormones major oral iron salts have been reported to chelate oral thyroid hormones within the gi tract when administered simultaneously leading to decreased thyroid hormone absorption to minimize the risk of interaction oral thyroid hormones should be administered at least 4 hours before or after the ingestion of iron supplements trientine major in general oral mineral supplements should not be given since they may block the oral absorption of trientine however iron deficiency may develop especially in children and menstruating or pregnant women or as a result of the low copper diet recommended for wilsons disease if necessary iron may be given in short courses but since iron and trientine each inhibit oral absorption of the other 2 hours should elapse between administration of trientine and iron doses zinc moderate orally administered zinc salts compete with iron supplements for absorption from the intestine to minimize the interaction separate oral iron and zinc doses by at least 2 hours the oral receipt of 100 mg of iron as ferrous gluconate with 12 mg zinc in 11 patients with normal iron status and comparable total exchangeable zinc pools yielded a mean zinc absorption of 264  144 of the administered dose as compared with 445  225 of the dose given without concomitant iron concomitant use of iron 400 mg as ferrous gluconate yielded a mean zinc absorption of 229  64 of the zinc dose pregnancy and lactationpregnancy use sodium ferric gluconate complex or ferric pyrophosphate citrate in pregnant patients only if the potential benefit justifies the potential risk to the fetus sodium ferric gluconate complex is classified as fda pregnancy category b there are no adequate or wellcontrolled human studies with sodium ferric gluconate complex in pregnancy sodium ferric gluconate complex was not teratogenic at doses up to 100 mgkgday 300 mgm2day in mice and 20 mgkgday 120 mgm2day in rats these iron doses were 4 and 15 times the recommended human dose of 125 mgday 77 mgm2day on a body surface area basis and revealed no evidence of harm to the fetus no data are available regarding maternal toxicity sodium ferric gluconate complex injection products contain benzyl alcohol as a preservative although there are no known adverse outcomes associated with fetal exposure to the preservative benzyl alcohol can cause serious adverse events and death when administered intravenously to neonates and infants studies to assess the effects of sodium ferric gluconate complex on fertility were not conducted there are no available data on the use of ferric pyrophosphate citrate in pregnant women to inform a drugassociated risk of major birth defects or miscarriage in animal studies with ferric pyrophosphate citrate developmental toxicity was observed when animals were administered maternally toxic doses that were higher than the maximum theoretical amount of iron administered to humans use caution when administering sodium ferric gluconate complex injection to a breastfeeding woman while iron is excreted into breast milk the iron content of breast milk is not readily affected by the iron content of the maternal diet or the maternal serum iron concentration therefore iron use is usually compatible with breastfeeding if the lactating mother needs treatment for iron deficiency however sodium ferric gluconate complex injection products contain the preservative benzyl alcohol when present in maternal serum benzyl alcohol is likely to cross into breast milk and may be orally absorbed by a nursing infant benzyl alcohol has been associated with gasping syndrome in neonates and lowbirth weight infants although a normal therapeutic dose of sodium ferric gluconate complex delivers a much smaller amount of benzyl alcohol than has been associated with gasping syndrome the potential for serious adverse events from exposure to benzyl alcohol especially in a neonate or lowbirth weight infant should be considered there is no information regarding the presence of ferric pyrophosphate citrate in human milk the effects on the breastfed child or the effects on milk production consider the developmental and health benefits of breastfeeding along with the mothers clinical need for ferric pyrophosphate citrate and any potential adverse effects on the breastfed child from ferric pyrophosphate citrate or the underlying maternal condition mechanism of actionnormal erythropoiesis depends on the concentration of iron and erythropoietin available in the plasma both being decreased in renal failure exogenous administration of erythropoietin increases red blood cell production and iron utilization contributing to iron deficiency in hemodialysis patients a therapeutic response to treatment with sodium ferric gluconate complex ferric pyrophosphate citrate is dependent upon the patients ability to use the iron use of iron is influenced by the cause of the deficiency as well as other illnesses that can affect normal erythropoiesis proteinenergy malnutrition can prevent the incorporation of iron into the erythrocyte regardless of the quantity of iron stored only when lean body mass expands will iron be used iron therapy alone does not increase red blood cell production administration of iron will only improve anemia associated with iron deficiency there is some concern that intravenously administered iron is not used appropriately by the body and little is available for use in the bone marrow both animal and human data indicate the bulk of intravenously administered iron is sequestered in the reticuloendothelial system ie liver spleen which could lead to hepatosplenic hemosiderosis an increase in iron storage without associated tissue damage parenterally administered iron predominantly accumulates in the kupffer cells of the livers macrophage system leading to less harm than excess body iron stored in the parenchyma this information is associated with injectable iron products containing dextran polysaccharides ironcontaining proteins and enzymes are important in oxidationreduction reactions especially those of the mitochondria iron is a component of myoglobin and several hemeenzymes including the cytochromes catalase and peroxidase iron is an essential component of the metalloflavoprotein enzymes and the mitochondrial enzyme alphaglycerophosphate oxidase ironcontaining proteins and enzymes are important in oxidationreduction reactions especially those of the mitochondria furthermore iron is a cofactor for enzymes such as aconitase and tryptophan pyrrolase iron deficiency not only causes anemia and decreased oxygen delivery it also reduces the metabolism of muscle and decreases mitochondrial activity iron deficiency can also lead to defects in learning or thermoregulation thus iron is important to several metabolic functions which are independent of its importance to erythropoesis pharmacokineticssodium ferric gluconate complex is administered intravenously ferric pyrophosphate citrate is added to a bicarbonate dialysate for hemodialysis therapy iron therapy dosage is individualized according to patient goals for serum iron levels iron storage parameters eg ferritin transferrin saturation and serum hemoglobin concentrations iron toxicity may occur with excessive or unnecessary iron therapy systemic iron is stored in compounds called ferritin and hemosiderin which are used for future use in the production of hemoglobin the absorption of iron depends upon the route of entry the tissue that first clears parenterally administered iron from the bloodstream determines the bioavailability if the reticuloendothelial system clears iron only small amounts will be available over time to the bone marrow transferrin accepts iron from the intestinal tract or from sites of storage or hemoglobin destruction iron is then transported in plasma bound to transferrin and distributed to the bone marrow for hemoglobin synthesis to the reticuloendothelial system for storage to all cells for enzymes containing iron and to placental cells to meet fetal needs transferrin eventually becomes available for reuse there is no destructive metabolism of iron because it takes place in a closed system in normal adults ninety percent of metabolized iron is conserved and reutilized repeatedly very little iron is excreted in normal healthy adults some daily loss of iron occurs through normal skin hair and nail loss and gi losses menstruating women have an increased loss as do other persons with loss of blood in vitro experiments with both diluted and undiluted sodium ferric gluconate complex demonstrate that less than 1 of the iron species within the compound is dialyzable sodium ferric gluconate complex approximately 80 of drug bound iron was delivered to transferrin as a mononuclear ionic iron species within 24 hours of administration in each dosage regimen direct movement of iron from sodium ferric gluconate complex was not observed mean peak transferrin saturation did not exceed 100 and returned to near baseline by 40 hours after administration of each dosage regimen ferric pyrophosphate citrate following intravenous infusion over 4 hours at 25 5 75 and 10 mg doses serum iron halflife was approximately 148 hours with a mean clearance cl ranging from 0406 to 0556 lhour and a volume of distribution vz ranging from 0765 to 0859 l higher mean clearance and volume of distributions were observed following 15 mg cl  0672 lhour and vz  166 l and 20 mg cl  0661 lhour vz  208l intravenously over 12 hours intravenous route sodium ferric gluconate complex multiple sequential single dose intravenous pharmacokinetic studies were performed on 14 healthy irondeficient patients patients were randomized to receive undiluted sodium ferric gluconate complex intravenously by slow iv infusion either 125 mg infused over 1 hour or 625 mg infused over 05 hour five days after the first stage each subject was rerandomized to undiluted sodium ferric gluconate complex intravenously by rapid iv infusion either 125 mg infused over 7 minutes or 625mg infused over 4 minutes cmax concentrations varied by dosage and rate of administration the highest cmax 190 mgl was observed in the group who received 125 mg by rapid iv infusion the initial volume of distribution of 6 l corresponds well to calculated blood volume the terminal elimination halflife was approximately 1 hour ranging from 085 hours for the 625 mg rapid iv infusion 4 minutes group to 145 hours for the 125 mg rapid infusion 7 minutes group total clearance was 302535 lhour the auc for sodium ferric gluconate complex varied by dose from 175 mghl for patients receiving 625 mg to 356 mghl for patients receiving 125 mg the rate of administration did not cause variation in the terminal elimination halflife clearance or auc other route sintravascular route ferric pyrophosphate citrate the pharmacokinetics of serum iron was investigated in healthy volunteers administered 25 5 75 and 10 mg ferric pyrophosphate citrate intravenously over 4 hours or 15 mg and 20 mg intravenously over 12 hours after correcting for the basal iron levels the auc and cmax of baselinecorrected serum iron increased in a dose proportional manner in a study that assessed the impact of different dialysis conditions on iron delivery in patients administered ferric pyrophosphate citrate via hemodialysis a reduction of the blood and dialysate flow rates qbqd of 200400 m lmin vs  350  600 m lmin resulted in a 33 decrease in the median cumulative iron delivered back to top 